News » Visby Medical Appoints Everett Cunningham to Board of Directors

05/25/2022Press Release

Visby Medical Appoints Everett Cunningham to Board of Directors

Visby Medical today announced Everett Cunningham has been appointed to the company’s Board of Directors.

Visby Medical Appoints Everett Cunningham to Board of Directors

SAN JOSE, Calif., May 25, 2022Visby Medical™, a leading medical diagnostic company, today announced Everett Cunningham has been appointed to the company’s Board of Directors. Cunningham is currently Chief Commercial Officer at Exact Sciences and brings 30 years of commercial experience in pharmaceuticals and molecular diagnostics to the company’s board.

“I am thrilled to welcome Everett to the Visby team,” said Visby Medical Founder and CEO Adam de la Zerda, Ph.D. “Everett is a dynamic executive with deep experience across the pharmaceutical and diagnostic industries. I look forward to his partnership and leadership; he will undoubtedly add tremendous value to the company during this exciting phase of growth.”

Cunningham brings a wealth of knowledge from leadership roles in large organizations, where he combined his commitment to excellence and responsibility with his passion for improving healthcare quality, access and affordability. He has been serving as Chief Commercial Officer at Exact Sciences since 2021. Previously, he served as President & CEO of GE Healthcare’s U.S. & Canada region, and was Senior Vice President, Commercial, at Quest Diagnostics.

“Visby has shown great success as an industry leader in infectious disease diagnostics with the world’s first instrument-free, single-use PCR platform to accurately and rapidly test for serious infections,” said Cunningham. “I am honored to join the board of such an innovative company that is dedicated to demonstrating a meaningful change in the diagnosis and treatment of infectious diseases.”

About Visby Medical™
Visby Medical is transforming the order of diagnosis and treatment for infectious diseases so clinicians can test, talk with, and treat the patient in a single visit. The Company’s proprietary technology development program culminated in the world’s first instrument-free, single-use PCR platform that fits in the palm of your hand and rapidly tests for serious infections. Originally developed for sexually transmitted infections, the Company’s FDA-cleared, CLIA-waived Sexual Health Click Test for women returns accurate results within 28 minutes. The Visby Medical technology is also helping to fight the global pandemic via the Visby Medical COVID-19 Test, and its robust pipeline includes tests for other infectious diseases. Visby Medical is accelerating the delivery of fast and accurate, palm-sized PCR diagnostics to the point of care, and eventually for use at home.

For more information, visit www.visbymedical.com. Follow Visby Medical on LinkedInFacebook, and Twitter.

Media Contact
Doug Hochstedler
press@visby.com

Read more articles & insights

02/21/2024Press Release

CARB-X awards funding to Visby Medical for gonorrhea, antibiotic susceptibility test

The Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) announced today that it will award biotechnology company Visby Medical of San Jose, California, up to $1.8 million to develop a portable polymerase chain reaction (PCR) test that can detect gonorrhea and assess its susceptibility to ciprofloxacin.

Read More
CARB-X awards funding to Visby Medical for gonorrhea, antibiotic susceptibility test

12/01/2023Viewpoint

Bracing for Winter Surges: The Imperative of PCR Point-of-Care Testing in Urgent Cares

As the chill in the air intensifies, healthcare systems worldwide brace themselves for a seasonal upswing in respiratory illnesses. This year, the situation is exacerbated by the continuing threat of COVID-19 alongside the potential resurgence of seasonal influenza (Flu A and Flu B).

Read More
Bracing for Winter Surges: The Imperative of PCR Point-of-Care Testing in Urgent Cares

11/18/2023Viewpoint

A Case Study on the Importance of Testing: When SARS-CoV-2 Meets Influenza A

In the setting of a global pandemic, the specter of SARS-CoV-2 infection has understandably dominated the differential diagnosis for respiratory symptoms. However, it is crucial to remember that other respiratory pathogens continue to circulate, potentially leading to varied clinical presentations in patients who share the same exposure or living environment.

Read More
A Case Study on the Importance of Testing: When SARS-CoV-2 Meets Influenza A

05/11/2023Viewpoint

Navigating the Post-Public Health Emergency Landscape: How the Visby Medical Respiratory Health Test EUA Remains Unaffected

As we move into the post-public health emergency landscape with the expiration of the national emergency concerning the coronavirus disease 2019 (COVID-19) pandemic on May 11, 2023, it is essential to understand how the healthcare industry has adapted and evolved to address the unique challenges posed by the COVID-19 pandemic.

Read More
Navigating the Post-Public Health Emergency Landscape: How the Visby Medical Respiratory Health Test EUA Remains Unaffected